메뉴 건너뛰기




Volumn 80, Issue 1, 2012, Pages 174-181

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: Further insights from a 12-month, comparative, phase III study in prostate cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 84862983937     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.01.092     Document Type: Article
Times cited : (24)

References (30)
  • 1
    • 34547193713 scopus 로고    scopus 로고
    • Guidelines on prostate cancer
    • Accessed: August 2011
    • A. Heidenreich, M. Bolla, S. Joniau Guidelines on prostate cancer Eur Assoc Urol 2011 2011 1 152 http://www.uroweb.org/gls/pdf/08-Prostate-Cancer.pdf Accessed: August 2011
    • (2011) Eur Assoc Urol , vol.2011 , pp. 1-152
    • Heidenreich, A.1    Bolla, M.2    Joniau, S.3
  • 2
    • 56649116179 scopus 로고    scopus 로고
    • The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    • L. Klotz, L. Boccon-Gibod, N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
    • (2008) BJU Int , vol.102 , pp. 1531-1538
    • Klotz, L.1    Boccon-Gibod, L.2    Shore, N.D.3
  • 3
    • 0022367715 scopus 로고
    • Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer
    • J. Waxman, A. Man, W.F. Hendry Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer Br Med J (Clin Res Ed) 291 1985 1387 1388 (Pubitemid 16212355)
    • (1985) British Medical Journal , vol.291 , Issue.6506 , pp. 1387-1388
    • Waxman, J.1    Man, A.2    Hendry, W.F.3
  • 4
    • 0025688334 scopus 로고
    • Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
    • I.M. Thompson, E.J. Zeidman, F.R. Rodriguez Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate J Urol 144 1990 1479 1480
    • (1990) J Urol , vol.144 , pp. 1479-1480
    • Thompson, I.M.1    Zeidman, E.J.2    Rodriguez, F.R.3
  • 5
    • 20344374658 scopus 로고    scopus 로고
    • Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone?
    • DOI 10.1016/j.eursup.2005.04.004, PII S1569905605000448, Prostate Cancer: Testosterone Suppression Levels and Eligard (R)
    • B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 4 2005 14 19 (Pubitemid 40780974)
    • (2005) European Urology, Supplements , vol.4 , Issue.5 , pp. 14-19
    • Tombal, B.1
  • 6
    • 43949144620 scopus 로고    scopus 로고
    • Management of advanced prostate cancer: Can we improve on androgen deprivation therapy?
    • DOI 10.1111/j.1464-410X.2008.07590.x
    • J. Anderson, P.A. Abrahamsson, D. Crawford Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 101 2008 1497 1501 (Pubitemid 351704035)
    • (2008) BJU International , vol.101 , Issue.12 , pp. 1497-1501
    • Anderson, J.1    Abrahamsson, P.-A.2    Crawford, D.3    Miller, K.4    Tombal, B.5
  • 10
    • 0030891205 scopus 로고    scopus 로고
    • Serum testosterone - A significant determinant of metastatic relapse for irradiated localized prostate cancer
    • DOI 10.1016/S0090-4295(96)00619-X, PII S009042959600619X
    • G.K. Zagars, A. Pollack, A.C. von Eschenbach Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer Urology 49 1997 327 334 (Pubitemid 27138671)
    • (1997) Urology , vol.49 , Issue.3 , pp. 327-334
    • Zagars, G.K.1    Pollack, A.2    Von Eschenbach, A.C.3
  • 12
    • 39149084101 scopus 로고    scopus 로고
    • Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies
    • DOI 10.1093/jnci/djm323
    • A.W. Roddam, N.E. Allen Endogenous Hormones and Prostate Cancer Collaborative Group Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 3 2008 170 183 (Pubitemid 351480553)
    • (2008) Journal of the National Cancer Institute , vol.100 , Issue.3 , pp. 170-183
    • Roddam, A.W.1    Allen, N.E.2    Appleby, P.3    Key, T.J.4
  • 13
    • 53249121469 scopus 로고    scopus 로고
    • A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
    • M. Gittelman, P.J. Pommerville, B.E. Persson A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 2008 1986 1992
    • (2008) J Urol , vol.180 , pp. 1986-1992
    • Gittelman, M.1    Pommerville, P.J.2    Persson, B.E.3
  • 14
    • 50849110501 scopus 로고    scopus 로고
    • Degarelix: A novel gonadotrophin-releasing hormone (GnRH) blocker - Results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer
    • H. Van Poppel, B. Tombal, J.J. de la Rosette Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 2008 805 813
    • (2008) Eur Urol , vol.54 , pp. 805-813
    • Van Poppel, H.1    Tombal, B.2    De La Rosette, J.J.3
  • 15
    • 77949653652 scopus 로고    scopus 로고
    • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
    • B. Tombal, K. Miller, L. Boccon-Gibod Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842
    • (2010) Eur Urol , vol.57 , pp. 836-842
    • Tombal, B.1    Miller, K.2    Boccon-Gibod, L.3
  • 16
    • 0028786511 scopus 로고
    • Bicalutamide in the treatment of advanced prostatic carcinoma: A phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
    • M.S. Soloway, P.F. Schellhammer, J.A. Smith Jr. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy J Urol 154 6 1995 2110 2114
    • (1995) J Urol , vol.154 , Issue.6 , pp. 2110-2114
    • Soloway, M.S.1    Schellhammer, P.F.2    Smith, Jr.J.A.3
  • 17
    • 0028875365 scopus 로고
    • Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial Zoladex Prostate Study Group
    • N.J. Vogelzang, G.W. Chodak, M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial Zoladex Prostate Study Group Urology 46 2 1995 220 226
    • (1995) Urology , vol.46 , Issue.2 , pp. 220-226
    • Vogelzang, N.J.1    Chodak, G.W.2    Soloway, M.S.3
  • 18
    • 77149159440 scopus 로고    scopus 로고
    • Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance?
    • M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 5 2010 648 651
    • (2010) BJU Int , vol.105 , Issue.5 , pp. 648-651
    • Perachino, M.1    Cavalli, V.2    Bravi, F.3
  • 19
    • 78549231887 scopus 로고    scopus 로고
    • Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer
    • M. Roach 3rd, K. Bae, C. Lawton Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 78 5 2010 1314 1322
    • (2010) Int J Radiat Oncol Biol Phys , vol.78 , Issue.5 , pp. 1314-1322
    • Roach III, M.1    Bae, K.2    Lawton, C.3
  • 20
    • 34547118594 scopus 로고    scopus 로고
    • The Importance of Testosterone Control in Prostate Cancer
    • DOI 10.1016/j.eursup.2007.06.002, PII S1569905607001728
    • B. Tombal The importance of testosterone control in prostate cancer Eur Urol Suppl 6 2007 834 839 (Pubitemid 47102240)
    • (2007) European Urology, Supplements , vol.6 , Issue.15 , pp. 834-839
    • Tombal, B.1
  • 21
    • 44549087997 scopus 로고    scopus 로고
    • What is new in hormone therapy for prostate cancer in 2007?
    • B. Tombal What is new in hormone therapy for prostate cancer in 2007? Eur Urol Suppl 7 2008 477 483
    • (2008) Eur Urol Suppl , vol.7 , pp. 477-483
    • Tombal, B.1
  • 22
    • 33646248080 scopus 로고    scopus 로고
    • Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer
    • R. Berges, U. Bello Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer Curr Med Res Opin 22 2006 649 655
    • (2006) Curr Med Res Opin , vol.22 , pp. 649-655
    • Berges, R.1    Bello, U.2
  • 23
    • 34548400276 scopus 로고    scopus 로고
    • Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy
    • DOI 10.1016/j.juro.2007.05.129, PII S0022534707014000
    • J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295 (Pubitemid 47368393)
    • (2007) Journal of Urology , vol.178 , Issue.4 , pp. 1290-1295
    • Morote, J.1    Orsola, A.2    Planas, J.3    Trilla, E.4    Raventos, C.X.5    Cecchini, L.6    Catalan, R.7
  • 24
    • 0035516095 scopus 로고    scopus 로고
    • A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
    • D. McLeod, N. Zinner, K. Tomera A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 2001 756 761
    • (2001) Urology , vol.58 , pp. 756-761
    • McLeod, D.1    Zinner, N.2    Tomera, K.3
  • 26
    • 80051764006 scopus 로고    scopus 로고
    • An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer
    • L. Boccon-Gibod, E. Van der Meulen, B.E. Persson An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer Ther Adv Urol 3 3 2011 127 140
    • (2011) Ther Adv Urol , vol.3 , Issue.3 , pp. 127-140
    • Boccon-Gibod, L.1    Van Der Meulen, E.2    Persson, B.E.3
  • 27
    • 0023859321 scopus 로고
    • Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer
    • J. Morote, A. Ruibal, J. Palou Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer Int J Biol Markers 3 1988 23 28
    • (1988) Int J Biol Markers , vol.3 , pp. 23-28
    • Morote, J.1    Ruibal, A.2    Palou, J.3
  • 28
    • 0024538468 scopus 로고
    • Changes in prostate-specific markers under chronic gonadotrophin- releasing hormone analogue treatment of stage D prostatic cancer
    • DOI 10.1002/1097-0142(19890401)63:7<1287::AID-CNCR2820630710>3.0. CO;2-7
    • H. Matzkin, O. Lewyshon, D. Ayalon Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer Cancer 63 1989 1287 1291 (Pubitemid 19084547)
    • (1989) Cancer , vol.63 , Issue.7 , pp. 1287-1291
    • Matzkin, H.1    Lewyshon, O.2    Ayalon, D.3    Braf, Z.4
  • 29
    • 0029077920 scopus 로고
    • Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
    • J.A. Storlie, J.C. Buckner, G.A. Wiseman Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96 100
    • (1995) Cancer , vol.76 , pp. 96-100
    • Storlie, J.A.1    Buckner, J.C.2    Wiseman, G.A.3
  • 30
    • 0031832733 scopus 로고    scopus 로고
    • Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    • D.C. Smith, R.L. Dunn, M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843 (Pubitemid 28234729)
    • (1998) Journal of Clinical Oncology , vol.16 , Issue.5 , pp. 1835-1843
    • Smith, D.C.1    Dunn, R.L.2    Strawderman, M.S.3    Pienta, K.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.